Physician profile
Charles E Jarreau
NPI 1346563681
$40,284.94
in general payments reported to CMS, 2019-2025
35 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,995 · 2022: $2,009 · 2023: $4,107 · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $6,457 · Travel and Lodging: $528 · Education: $33.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,262.50 |
| Food and Beverage | $6,456.54 |
| Travel and Lodging | $528.28 |
| Education | $33.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,133.74 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $13,187.54 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,397.89 | 2021-2025 | Krystexxa, Tavneos, Evenity |
| Astrazeneca Pharmaceuticals Lp | $1,164.89 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Otsuka America Pharmaceutical, INC. | $837.53 | 2021-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $703.57 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $591.88 | 2021-2025 | Ultomiris |
| Novo Nordisk INC | $486.15 | 2021-2025 | Ozempic, Rivfloza, Rybelsus |
| Fresenius USA Marketing, INC. | $466.03 | 2021-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $325.33 | 2021-2025 | Acthar |
| Vifor Pharma, INC. | $325.05 | 2021-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $277.75 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $251.08 | 2021-2023 | |
| Opko Pharmaceuticals, LLC | $230.09 | 2021-2024 | Rayaldee |
| Akebia Therapeutics INC | $228.94 | 2021-2025 | Vafseo, Auryxia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $212.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $204.86 | 2021-2023 | Jesduvroq |
| Horizon Therapeutics Plc | $190.90 | 2022-2023 | Krystexxa |
| Medtronic, INC. | $186.74 | 2021-2024 | Minimed 780g |
| Travere Therapeutics, INC. | $168.73 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $145.86 | 2022-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $127.89 | 2021-2023 | Lupkynis |
| Cormedix INC. | $72.31 | 2024-2025 | Defencath, Defencath |
| Xeris Pharmaceuticals, INC. | $68.31 | 2023-2025 | Gvoke Hypopen |
| Ardelyx, INC. | $47.84 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $43.19 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $39.30 | 2021 | |
| Scpharmaceuticals INC. | $31.24 | 2025 | |
| Ani Pharmaceuticals, INC. | $27.06 | 2024 | Purified Cortrophin Gel |
| Recordati_rare_diseases_inc. | $26.01 | 2021 | |
| Dexcom, INC. | $21.62 | 2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $17.61 | 2021 | |
| Esperion Therapeutics, INC. | $17.04 | 2021 | |
| Outset Medical INC | $14.81 | 2022 | |
| Shield Therapeutics INC | $13.24 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Jarreau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.